Mosquito Borne Disease Market, By Disease Type (Malaria, Dengue, Yellow Fever, West Nile Virus, Chikungunya, Zika Virus, and Others), By Treatment Type (Medication, Vaccination, Vector Control Methods, Immunotherapy, Supportive Care, and Others), By End User (Hospitals, Clinics, Diagnostic Centers, Research Institutes, Government Organizations, NGOs, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Nov 2023

Code : CMI6241

Pages :150

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Mosquito Borne Disease Market- Recent Developments

New Product Launches

In September 2022, GSK, a pharmaceutical company, announced that the World Health Organization (WHO) had awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK’s groundbreaking malaria vaccine. This is the first prequalification for a malaria vaccine, It is a crucial stage in the vaccination program's introduction in nations where P. falciparum malaria transmission is moderate to high.
In July 2022, GSK, a pharmaceutical company, announced that it had received approval for Mosquirix, the first malaria vaccine, by European Medicines Agency (EMA). Mosquirix acts against plasmodium falciparum malaria which is most prevalent in Africa. This vaccine has potential to save thousands of lives.
In August 2021, The International Vaccine Institute (IVI), an independent, nonprofit, international organization, announced that the first participant received Bharat Biotech International Ltd’s (BBIL), a leading vaccines & bio-therapeutics manufacturers, Chikungunya vaccine candidate (BBV87) in a Phase II/III clinical trial in Costa Rica, marking the start of a multi-country study led by IVI in partnership with BBIL and funded by the Coalition for Epidemic Preparedness Innovations (CEPI) with support from the Ind-CEPI mission of the Department of Biotechnology, India
In June 2021, Bharat Biotech, a leading vaccines & bio-therapeutics manufacturers, announced the launch of Chikungunya vaccine with brand name Chikungunya Vacc-DCV in India. This vaccine has potential to reduce chikungunya disease burden in India and globally.

Acquisition, Agreement, Partnerships and Research & Development Activities

On October 11, 2023, UNICEF, United Nations International Children's Emergency Fund, announced an agreement with Serum Life Sciences for the year 2024 – 2028 for vaccine pre-qualification from the World Health Organization, to secure supply of the world’s second malaria vaccine, R21/Matrix-M. The deal is a major milestone towards meeting the high demand for doses of new vaccines against malaria – a disease which still kills one child under five every minute.
In June 2022, GSK, a pharmaceutical company, acquired Affinivax Inc, a clinical stage biopharmaceutical company pioneering a novel vaccine technology platform. This US$ 2.1 billion acquisition enhanced GSK's vaccines research and development capabilities and pipeline for diseases like pneumonia.
In December 2021, GSK, a pharmaceutical company, and Medicago, a biotechnology company, announced positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects (adults 18 years and above) across six countries
In July 2020, GSK, a pharmaceutical company, and Medicago, a biotechnology company, announced a partnership to jointly develop plant-derived COVID-19 vaccines. Under this partnership, GSK provided adjuvant for Medicago's COVID-19 vaccine candidate, enhancing immunogenicity.